Discussion
Reducing doses of antifibrotic medications when side effects make treatment difficult to tolerate was not linked to a significantly higher risk of disease progression in people with idiopathic pulmonary fibrosis (IPF), a real-world study found. The study included more than 1,500 people with IPF. More than 30% received lower…